HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies
Science Advances · 2025
DOI: 10.1126/sciadv.adv6723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Daimin Xiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University,…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Gallbladder Neoplasms, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Cell Self Renewal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Gallbladder cancer (GBC) is the most common malignancy in the biliary system and lacks biomarkers for personalized therapy. Here, we reported that hepatic leukemia factor (HLF) was highly expressed in gallbladder cancer stem cells (CSCs) and patients with gemcitabine-resistant GBC. Mechanistic study revealed that interleukin-6 receptor (IL-6R) and transcription factor EB (TFEB) are direct target genes of HLF. The IL-6/IL-6R/signal transducer and activator of transcription 3 axis transactivates HLF expression in GBC, forming a positive feedback loop. Functional studies revealed that HLF promoted gallbladder CSCs’ expansion and gemcitabine resistance via TFEB-induced autophagy. In addition, HLF drives TFEB-induced programmed death ligand 1 expression in human tumors and governs tumor immune evasion in a CD8 + T cell–dependent manner. Patient cohorts’ analysis suggested that HLF levels in GBCs might determine the distinct responses to chemotherapy and immunotherapy. In conclusion, our findings demonstrated that HLF could act as a driver for gallbladder CSCs’ self-renewal and drug resistance and a biomarker for individualized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.
- Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
- Department of Hepatobiliary Surgery, Third Affiliated Hospital of Naval Military Medical University, Shanghai 200438, China.
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
ORCID-Profile: Daimin Xiang, Zhao Yang, Mingye Gu, Midie Xu, Erdong Liu, Hongyang Wang, Jing Fu
Zitieren
APA
Xiang, D., Yang, Z., Gu, M., Xu, M., Liu, C., Liu, E., Liu, J., Wang, Y., Wang, H., & Fu, J. (2025). HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies. Science Advances. https://doi.org/10.1126/sciadv.adv6723
Vancouver
Xiang D, Yang Z, Gu M, Xu M, Liu C, Liu E, et al. HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies. Science Advances. 2025. doi:10.1126/sciadv.adv6723
BibTeX
@article{Xiang2025,
author = {Xiang, Daimin and Yang, Zhao and Gu, Mingye and Xu, Midie and Liu, Chunliang and Liu, Erdong and Liu, Junyu and Wang, Yichuang and Wang, Hongyang and Fu, Jing},
title = {HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adv6723}
}
EUVIMED